LRMR LARIMAR THERAPEUTICS INC revenue, earnings and financials
For the quarter ended June 30, 2026, LARIMAR THERAPEUTICS INC reported revenue of n/a, net income of −$32.8M and diluted EPS of n/a; for the fiscal year ended December 2025 revenue was n/a.
LRMR annual revenue and earnings
- Fiscal year ended Dec 2025: revenue n/a, gross profit n/a, operating income −$172M, net income −$166M (margin n/a), EPS n/a
- Fiscal year ended Dec 2024: revenue n/a, gross profit n/a, operating income −$90.9M, net income −$80.6M (margin n/a), EPS −$1.32
- Fiscal year ended Dec 2023: revenue n/a, gross profit n/a, operating income −$41.8M, net income −$36.9M (margin n/a), EPS −$0.84
- Fiscal year ended Dec 2022: revenue n/a, gross profit n/a, operating income −$36.5M, net income −$35.4M (margin n/a), EPS −$1.37
- Fiscal year ended Dec 2021: revenue n/a, gross profit n/a, operating income −$50.5M, net income −$50.6M (margin n/a), EPS −$2.95
LRMR quarterly revenue and earnings
- Quarter ended Jun 30, 2026: revenue n/a, net income −$32.8M, EPS n/a
- Quarter ended Mar 31, 2026: revenue n/a, net income −$29.6M, EPS n/a
- Quarter ended Dec 31, 2025 (from the annual report): revenue n/a, net income −$62.5M, EPS n/a
- Quarter ended Sep 30, 2025: revenue n/a, net income −$47.7M, EPS −$0.61
- Quarter ended Jun 30, 2025: revenue n/a, net income −$26.2M, EPS −$0.41
- Quarter ended Mar 31, 2025: revenue n/a, net income −$29.3M, EPS −$0.46
- Quarter ended Dec 31, 2024 (from the annual report): revenue n/a, net income −$28.8M, EPS −$0.47
- Quarter ended Sep 30, 2024: revenue n/a, net income −$15.5M, EPS −$0.24
- Quarter ended Jun 30, 2024: revenue n/a, net income −$21.6M, EPS −$0.34
- Quarter ended Mar 31, 2024: revenue n/a, net income −$14.7M, EPS −$0.27
- Quarter ended Dec 31, 2023 (from the annual report): revenue n/a, net income −$13.0M, EPS −$0.29
- Quarter ended Sep 30, 2023: revenue n/a, net income −$9.06M, EPS −$0.21
- Quarter ended Jun 30, 2023: revenue n/a, net income −$8.37M, EPS −$0.19
- Quarter ended Mar 31, 2023: revenue n/a, net income −$6.53M, EPS −$0.15
- Quarter ended Dec 31, 2022 (from the annual report): revenue n/a, net income −$9.43M, EPS −$0.04
- Quarter ended Sep 30, 2022: revenue n/a, net income −$8.32M, EPS −$0.37
- Quarter ended Jun 30, 2022: revenue n/a, net income −$8.67M, EPS −$0.47
- Quarter ended Mar 31, 2022: revenue n/a, net income −$8.94M, EPS −$0.49
- Quarter ended Dec 31, 2021 (from the annual report): revenue n/a, net income −$9.13M, EPS −$0.48
- Quarter ended Sep 30, 2021: revenue n/a, net income −$16.8M, EPS −$0.92
LRMR cash flow, buybacks and dividends
- Fiscal year ended Dec 2025: operating cash flow −$113M, share buybacks n/a
- Fiscal year ended Dec 2024: operating cash flow −$70.8M, share buybacks n/a
- Fiscal year ended Dec 2023: operating cash flow −$33.5M, share buybacks n/a
- Fiscal year ended Dec 2022: operating cash flow −$27.6M, share buybacks n/a
- Fiscal year ended Dec 2021: operating cash flow −$42.1M, share buybacks n/a
LRMR balance sheet
- Jun 30, 2026: cash $92.7M, total assets $165M, total liabilities $37.9M, shareholders' equity $127M
- Mar 31, 2026: cash $178M, total assets $209M, total liabilities $50.5M, shareholders' equity $158M
- Dec 31, 2025: cash $85.4M, total assets $146M, total liabilities $67.8M, shareholders' equity $78.1M
- Sep 30, 2025: cash $90.1M, total assets $187M, total liabilities $48.3M, shareholders' equity $139M
- Jun 30, 2025: cash $20.6M, total assets $150M, total liabilities $30.1M, shareholders' equity $120M
- Mar 31, 2025: cash $21.1M, total assets $170M, total liabilities $25.9M, shareholders' equity $144M
- Dec 31, 2024: cash $33.2M, total assets $200M, total liabilities $28.4M, shareholders' equity $172M
- Sep 30, 2024: cash $35.1M, total assets $219M, total liabilities $20.6M, shareholders' equity $198M
Is LRMR profitable?
No. LARIMAR THERAPEUTICS INC lost $173M over the last four quarters.